IO Biotech clinical trials we track

Check company identity source

Phase 3 1 trial

TrialDrugs studiedStatusPrimary completion
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)NCT05155254IO102-IO103, PembrolizumabActive not recruiting2025-05-30Actual

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: ORR or PFS. After: Measure: ORR.

Primary completion date changed

Before: 4 Jan 2024. After: 30 Nov 2025.

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source